Rituximab would be authorized to treat relapsed or refractory chronic lymphocytic leukemia in combination with fludarabine and cyclophosphamide under a draft guideline published by the clinical effectiveness agency for England and Wales.The guidance published Nov. 10 by the National Institute for Health and Clinical Excellence states that the agent can be used except when patients have been treated with rituximab previously, or if the patient has not responded to fludarabine or has relapsed within...